Last reviewed · How we verify
UB-621
At a glance
| Generic name | UB-621 |
|---|---|
| Sponsor | United BioPharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 (PHASE2)
- Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes (PHASE2)
- UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals (PHASE2)
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UB-621 CI brief — competitive landscape report
- UB-621 updates RSS · CI watch RSS
- United BioPharma portfolio CI